IMR-687

· Cardurion Pharmaceuticals, Inc.

Drug timelines are a Plus or Pro feature.

6 regulatory and trial events tracked for IMR-687, covering 2022-03-04 to 2025-05-15. Get the full timeline:

Most recent: Clinical Trial Update: Selective PDE9 Inhibition With IMR-687 in Adults With Heart Failure With Preserved Ejection Fraction [Phase 2]